NEUROCRINE BIOSCIENCES INC cotiza a 135.13 USD y tiene una capitalización bursátil de $13.7B. En los últimos 12 meses ha facturado $3.4B con un margen de flujo de caja libre del 26.2%. Cotiza a 15.8 veces su flujo de caja libre (P/FCF) y a un PER de 19.5. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tab…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.85 | $1.94 | $1.88 |
| Estimado | $2.73 | $1.96 | $1.70 | $2.30 |
| Sorpresa | — | +45.4% | +14.1% | -18.3% |
| Métrica | NBIX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 98.2% | 57.0% | +41.1% |
| Operating Margin | 21.6% | -38.6% | +60.3% |
| Net Margin | 16.7% | -33.6% | +50.3% |
| FCF Margin | 26.2% | -13.9% | +40.0% |
| ROE | 14.7% | -40.4% | +55.1% |
| ROA | 10.3% | -32.0% | +42.3% |
| Current Ratio | 3.39 | 2.84 | +0.55 |
| Debt / Equity | — | 0.28 | — |